Partecipazioni

Abenex enters into exclusive negotiations with DENTRESSANGLE Capital for the sale of EDL, a European player in software for medical imaging and diagnostic services

Settembre 2024

EDL, based in Berre l'Etang (13), is a European player and French leader (150 employees, turnover of c.€30m) in software dedicated to medical imaging platforms in healthcare establishments, thanks to its Xplore software suite.

Under the impetus of the management team and Abenex, EDL has developed strongly in Germany, Switzerland, Austria and more recently in Belgium.

DENTRESSANGLE Capital and Kylian Lopez, CEO of EDL, will continue this European expansion while strengthening the software's technological lead by continuously improving the functionalities offered to practitioners and healthcare professionals.

Abenex has entered into exclusive negotiations with DENTRESSANGLE Capital for the exit of EDL, a European leading software provider for medical imaging and diagnostic services. Xplore: the market-leading medical imaging software EDL, Founded in 1994 in the Bouches-du-Rhône region of France, has since developed the Xplore software suite, providing customers with a comprehensive, integrated web solution for enhancing information sharing and optimizing the operation of technical platforms in both public and private healthcare establishments. The company’s solutions are widely recognised for their technological leadership and proven robustness. This is particularly the case among practitioners and operators, who value the ergonomics, functional coverage of EDL’s solutions. The Xplore software suite enables an effective deployment of teleradiology in multi-site organisations, thus improving patient care and management by facilitating the exchange of examinations. An advanced new offering incorporating Artificial Intelligence (AI) Following excellent customer feedback, practitioners and operators, EDL has innovated and adapted its solutions to extend its offering beyond medical imaging to meet the needs of medical diagnostics departments. Furthermore, EDL has dedicated its R&D resources to the progressive incorporation of Artificial Intelligence (AI) across its product range. This has led to the development of a platform of diagnostic assistance algorithms for healthcare professionals. A leading European player Since 2021, EDL has expanded its European presence through strategic strengthening positions in Germany and Switzerland, driven by the combined impetus of its management team and Abenex. The company has also strengthened its presence in Belgium through the acquisition of Thélème, specialist in software for nuclear medicine, more recently in Austria. The appointment of Kylian Lopez as CEO in May 2024, after 10 years developing the company's business and rolling out the Xplore solution, presents opportunities for growth in other major European markets. Kylian Lopez and the management team are also reinvesting significantly alongside DENTRESSANGLE Capital to provide EDL with the financial resources required to expand its product range and accelerate its development. In addition, historic founders have also decided to reinvest, testimony to their renewed trust in the Group’s future prospects. Kylian Lopez, CEO of EDL, “With Abenex's support, EDL has become a major player in Europe. I'm now delighted to embark on a new cycle with DENTRESSANGLE Capital, a player renowned for its ability to grow businesses alongside entrepreneurs. Our goal is to accelerate our growth and development to become a European leader in medical imaging, nuclear medicine and cardiology, with the continuous ambition to provide solutions that help physicians to focus on the diagnosis and management of their patients” EDL has capitalised on its technological expertise to diversify its product portfolio beyond medical imaging, addressing the unmet needs of nuclear medicine, cardiology and functional exploration departments Jérôme Vandermarcq, Partner in the Abenex Mid-Cap team, “We are proud to have supported the EDL Group's development over the past three years. EDL has significantly accelerated its growth, strengthening its position as the leading radiology software provider in France. The Group has been able to leverage the quality and technological edge of its solutions to expand its diagnostics offering thanks to a strong R&D culture. EDL is now well positioned to be embarking on a new phase of growth in the European market.” Olivier Verdet, Partner at Dentressangle, “EDL has experienced significant growth in recent years, driven by a forward-thinking management team and the strategic support of Abenex. The company is now a significant player in the medical imaging software market, operating in both the public and private sectors. We are pleased to be involved in this venture, supporting the company as it accelerates its European expansion and extends its influence in the diagnostics sector.”

← → Naviga tra le pubblicazioni

Abenex enters into exclusive negotiations with DENTRESSANGLE Capital for the sale of EDL, a European player in software for medical imaging and diagnostic services

Abenex invests in Santis LAB alongside its founders and management team

Abenex announces three new promotions across its teams